1172P High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC)

Abstract

Poziotinib is an oral pan-ErbB tyrosine kinase inhibitor (TKI) with demonstrated clinical activity and an expected safety profile. Patients with NSCLC harboring HER2 exon 20 insertion mutations (ex20ins) have poor outcomes and lack approved targeted treatments. The G778_P780dup (G778) mutation is one of the most common, representing 9-19% of HER2 ex20ins in NSCLC. Previous studies have reported an overall response rate (ORR) ranging from 10-60% with TKIs in patients with G778. Here we report the effects of poziotinib in patients harboring the HER2 ex20ins G778 mutation in a relatively large population of treatment-naïve (C4) and previously treated (C2) patients with NSCLC.